在轻度至中度的COVID-19中对Leronlimab进行随机的安慰剂控制试验
Harish Seethamraju1, Otto O Yang2, Richard Loftus3
1Montefiore Medical Center, Bronx, New York.
Clinical therapeutics
|October 1, 2024
概括
在一项随机试验中,Leronlimab没有改善COVID-19症状. 然而,一项后期分析表明,莱伦利马布可能会减少轻度至中度COVID-19患者的疾病进展.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 临床医学 临床医学
背景情况:
- 宿主基因,包括CCR5-Δ32突变,被假定会影响COVID-19的严重程度.
- 莱伦利马布是一种CCR5特异性抗体,被调查其对COVID-19的潜在影响.
- 了解SARS-CoV-2病理生理学对于开发有效的治疗方法至关重要.
研究的目的:
- 评估莱伦利马布在减轻轻度至中度COVID-19患者疾病症状方面的疗效.
- 探索勒龙利马布对症状评分和疾病进展的影响.
主要方法:
- TEMPEST试验是一项随机,双盲,安慰剂控制的研究.
- 参与者在第0天和第7天接受皮下莱伦利马布 (700毫克) 或安慰剂.
- 主要终点是14日总症状得分的变化.
主要成果:
- 莱伦利马布和安慰剂组之间总症状评分变化没有显著差异.
- 后期分析显示,在50%的莱伦利马布接受者中,国家早期预警评分2 (NEWS2) 得到改善,而在安慰剂接受者中,这一比例为20.8% (p=0.0223).
- 与安慰剂 (50.0%) 相比,莱伦利马布组的不良事件发生率在数值上较低 (33.9%).
结论:
- 莱伦利马布没有满足轻度至中度COVID-19症状改善的初级终点.
- 探索性分析表明,leronlimab可能会降低疾病进展的可能性.
- 需要进一步的临床试验来证实这些发现.
相关概念视频
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:29Coronavirus
Coronaviruses, including the severe acute respiratory syndrome coronavirus (SARS-CoV), are enveloped viruses characterized by their single-stranded, positive-sense RNA genome and helical nucleocapsid structure. The hallmark of these viruses is their club-shaped spike (S) glycoproteins that protrude from the viral envelope, facilitating attachment to host cells. Typically, coronaviruses infect the upper respiratory tract, often causing mild or asymptomatic disease. However, certain strains like...